July 12, 2023: International Precision Oncology Tumor Board: MSK & Sir HN Reliance Foundation Hospital: Targeting the BRAF Pathway

July 12, 2023: International Precision Oncology Tumor Board – Targeting the BRAF Pathway: MSK & Sir HN Reliance Foundation Hospital Interpreting results from next-generation genomic sequencing of cancer, and identifying the right drug for the right patient, is a challenge for many cancer specialists today. Join leading global experts for a new educational series from MSK, where we’ll take a deep…

Read the full article here

Source: Memorial Sloan Kettering Cancer Center

Categories: Hem/Onc News and Journals, Latest Headlines

Tweets with this article

Memorial Sloan Kettering Cancer Center

On 7/12, MSK continues our global educational series on molecular oncology, featuring experts from @TataMemorial @TMCKolkata @Basavatarakam to examine the BRAF cancer signaling pathway & discuss nuances of precision therapies. Register today: https://t.co/2ppJZwPN7t https://t.co/78gAQBb2IR

| Memorial Sloan Kettering Cancer Center

The Rockefeller Outpatient Pavilion at 53rd Street is temporarily closed following an isolated fire in a non-clinical area on Sunday evening. The fire was quickly…

Memorial Sloan Kettering Cancer Center August 21, 2023

MSK Research Highlights July 17, 2023

New MSK research identified a way to reduce toxicity in CAR T cell therapy; discovered a division of labor in DNA repair that suggests a…

July 18, 2023

July 12, 2023: International Precision Oncology Tumor Board: MSK & Sir HN Reliance Foundation Hospital: Targeting the BRAF Pathway

July 12, 2023: International Precision Oncology Tumor Board – Targeting the BRAF Pathway: MSK & Sir HN Reliance Foundation Hospital Interpreting results from next-generation genomic…

Sewanti Limaye 🇮🇳🇺🇸 July 12, 2023

When a cancer drug trial has a 100% success rate, you want to know who’s behind it. (It’s Luis Diaz Jr.)

Oncologist Luis Diaz Jr., at Memorial Sloan Kettering, achieved a breakthrough in cancer treatment. He focused on tumors with MMR deficiency.

July 6, 2023

Food as Medicine: Why One Doctor Thinks Diet Could Help Control Cancer

When Dr. Urvi Shah was diagnosed with Hodgkin lymphoma in 2016 during her first year as a hematology-oncology fellow, she heard lots of recommendations from…

Urvi Shah July 6, 2023

CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results – Nature Medicine

Prophylactic subcutaneous administration of anakinra, an IL-1 receptor inhibitor, reduced severe immune effector cell-associated neurotoxicity syndrome incidence in patients with relapsed or refractory large B-cell…

July 5, 2023

Related Articles